Komori
Earnings4881FunPep Company LimitedPharmaceuticals

Financial Results Summary for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated)

Business revenue was ¥1 million in the 2026 interim period, while operating, ordinary and net losses all narrowed from the same period of the previous year. However, the Company continues not to provide a full-year earnings forecast because negotiations with prospective new business partners remain uncertain.

Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
371
¥ million (reduction in operating loss)
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedJapanese GAAP
Net Sales1¥ million
Operating profit-538¥ million
Ordinary income-535¥ million
Net income attributable to owners of the parent-566¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share¥(12.66)
Financial position at period-end
Total assets2,109¥ million
of which net assets 1,675 ¥ millionEquity ratio 78.1%vs. prior year-end +5.4pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Annual Dividend Forecast¥0.00 → ¥0.00
Factors Behind Changes in Business Performance

Research and development expenses decreased by ¥357 million due to lower development costs for FPP004X, while other selling, general and administrative expenses also decreased by ¥13 million.

Disclosure regarding the going concern assumption

No applicable matters.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNo change (no new or excluded companies)
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Impairment Loss on Investment Securities ¥29,970 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End50,666,700 Shares
Treasury Shares at Period-End12 Shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 January 2026–30 June 2026
Net Sales¥1 million
Operating profit¥-538 million
Ordinary income¥-535 million
Profit attributable to owners of the parent¥-566 million
Net income per share¥(12.66)
Equity ratioEnd of the current fiscal period 78.1 / End of previous period 72.7
Total assets¥2,109 million
Net assets¥1,675 million
Annual Dividend Forecast¥0.00 → ¥0.00
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss Impairment Loss on Investment Securities ¥29,970 thousand
Disclosure regarding the going concern assumptionNo applicable matters.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNo change (no new or excluded companies)
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End50,666,700 Shares
Treasury Shares at Period-End12 Shares
Factors Behind Changes in Business PerformanceResearch and development expenses decreased by ¥357 million due to lower development costs for FPP004X, while other selling, general and administrative expenses also decreased by ¥13 million.
Items this document does not state (16)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Research and development expenses decreased by ¥357 million due to lower development costs for FPP004X, while other selling, general and administrative expenses also decreased by ¥13 million. A full-year earnings forecast has not been provided because business revenue depends on the status of negotiations with prospective new business partners and other factors, making a reasonable estimate difficult at this time.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Summary for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [Japanese GAAP] (Consolidated) | FunPep Company Limited (4881) timely disclosure | Komori